LEIDEN, The Netherlands, November 1 /PRNewswire/ -- OctoPlus N.V. , the drug delivery and development company, announced today that its CBO and CFO will present at industry conferences next week.
Gerben Moolhuizen, Chief Business Officer, will present on Tuesday November 7 at 8:45 AM, at BIO-Europe in Duesseldorf.
Hans Pauli, Chief Financial Officer, will present on Wednesday November 8 at 4:50 PM, at the Cowen Annual Global Health Care Conference in London.
About OctoPlus
OctoPlus N.V. is a product-oriented biopharmaceutical company committed to the development of improved pharmaceutical products that are based on its proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. Rather than seeking to discover novel drug candidates through early stage research activities, OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics and other drugs.
OctoPlus currently has five product candidates in development, of which three are in clinical trials. The lead product candidate, LocteronTM, is a novel interferon alfa combined with OctoPlus’ proprietary PolyActiveTM drug delivery technology for the treatment of chronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer side effects than marketed forms of interferon alfa which currently represent the standard of care for this disease. With its development partner Biolex Therapeutics, OctoPlus intends to commence a Phase IIa clinical trial of Locteron in the fourth quarter of 2006. The second clinical-stage product candidate is OP-145, a novel proprietary peptide therapeutic that is currently in clinical Phase II for the treatment of chronic middle ear infection. OctoPlus’ third product candidate in clinical development is hGH-OctoDEXTM, a novel formulation of recombinant human growth hormone for growth hormone deficiency. hGH-OctoDEX is in Phase I clinical trials and is based on OctoPlus’ proprietary OctoDEXTM technology. OctoPlus is also developing single-shot vaccines based on its proprietary OctoVAXTM platform. HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitis vaccination are currently in pre-clinical trials.
OctoPlus is also a leading provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industry, with a focus on difficult to formulate active pharmaceutical ingredients in injectable formulations. The earnings and expertise that OctoPlus derives from rendering formulation and manufacturing services help to support its own drug development programs.
OctoPlus is listed on Euronext Amsterdam since October 4, 2006 under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl.
This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus N.V. and the industry in which it operates. These statements are based on OctoPlus N.V.'s current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words “expect”, “anticipate”, “predict”, “estimate”, “project”, “plan”, “may”, “should”, “would”, “will”, “intend”, “believe” and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.
OctoPlus BV
CONTACT: For further information, please contact: OctoPlus, RianneRoukema, Corporate Communications +31-(71)-524-4044
